Innerva Pharmaceuticals develops novel treatment for Ocular Surface Pain.
Innerva Pharmaceuticals has raised $2.3M in total funding. The most recent round was Seed. The last funding was announced in October 2022.
Innerva Pharmaceuticals's investors include Inveready.
Innerva Pharmaceuticals is headquartered in Barcelona, Spain.
Innerva Pharmaceuticals develops novel treatment for Ocular Surface Pain.
Innerva Pharmaceuticals is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Innerva Pharmaceuticals — Funding & Investors." VCBacked, October 31, 2022, https://www.vcbacked.co/company/innerva-pharmaceuticals. Accessed October 3, 2026.
VCBacked. (2022). Innerva Pharmaceuticals — Funding & Investors. Retrieved October 3, 2026, from https://www.vcbacked.co/company/innerva-pharmaceuticals
{{cite web |title=Innerva Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/innerva-pharmaceuticals |website=VCBacked |access-date=October 3, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated